Northland Securities Initiates Coverage on Bio-Rad (BIO) with an Outperform
More News related to BIO
- BioInformatics, LLC New Report - The Market Outlook for Research Products in FY2010
- BioAlliance Pharma Presents Efficacy and Safety Preclinical Results for Its AMEP(TM) Anti-Invasive Biotherapy at The ESGCT Annual Congress in Hannover, November 21 to 25, 2009
- BioAlliance Pharma ranked as France's fastest growing company in the 2009 Deloitte Technology Fast 50(TM)
- Vernier and Bio-Rad to Offer Enhanced Solutions for Biotechnology Education
- Trading Outlook for Vermillion Inc. Issued by StockPreacher.com
More News related to New Coverage
- JANCO Partners Downgrades Energy Conversion Devices (ENER) to Sell
- Feltl & Co. Downgrades ArcSight (ARST) to Sell
- Credit Suisse Downgrades Comcast (CMCSA) to Neutral
- Citi Downgrades AK Steel (AKS) to Hold
- Citi Downgrades Netflix (NFLX) to Hold
Northland Securities initiates coverage on Bio-Rad Laboratories (NYSE: BIO) with an Outperform. Price target $88.
To see more analyst ratings on BIO Click Here.
Bio-Rad Laboratories, Inc. (Bio-Rad) manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.
Related Categories
New CoverageStocks Mentioned
+1.96Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
